Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) EBIT (2017 - 2025)

Cue Biopharma's EBIT history spans 9 years, with the latest figure at -$7.6 million for Q3 2025.

  • For Q3 2025, EBIT rose 13.85% year-over-year to -$7.6 million; the TTM value through Sep 2025 reached -$38.2 million, up 16.49%, while the annual FY2024 figure was -$41.5 million, 20.42% up from the prior year.
  • EBIT for Q3 2025 was -$7.6 million at Cue Biopharma, up from -$8.6 million in the prior quarter.
  • Across five years, EBIT topped out at -$7.6 million in Q3 2025 and bottomed at -$14.9 million in Q4 2022.
  • The 5-year median for EBIT is -$12.3 million (2025), against an average of -$11.5 million.
  • The largest annual shift saw EBIT plummeted 88.34% in 2022 before it soared 30.36% in 2024.
  • A 5-year view of EBIT shows it stood at -$7.9 million in 2021, then tumbled by 88.34% to -$14.9 million in 2022, then rose by 6.96% to -$13.8 million in 2023, then surged by 30.36% to -$9.6 million in 2024, then grew by 21.16% to -$7.6 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's EBIT are -$7.6 million (Q3 2025), -$8.6 million (Q2 2025), and -$12.3 million (Q1 2025).